Amer Zeidan عامر زيدان ✓

@Dr_AmerZeidan · New haven, CT, USA · joined 29 Jun 2019

Cancer doctor. Leukemia fighter. Hala @RealMadrid. Focus on #AMLsm & #MDSsm. Opinions are solely my own. COI https://t.co/6XkF8Cn1hi

26 603Followers

261Following

17 827Posts total

12.7KViews on collected posts

Últimas publicaciones

Amer Zeidan عامر زيدان ✓@Dr_AmerZeidan7 Sep

This is a good example why I don't trust AI and take everything that it says with a grain of salt. I asked about the definition of EFS in #MDSsm using IWG 2026 (and there are no 2026 criteria, the latest iteration was 2023), but it gave a completely misleading answer that talks h

1.7K views · 17 likes · 3 reposts · 3 replies Open on X →

Amer Zeidan عامر زيدان ✓@Dr_AmerZeidan7 Sep

@Dr_AmerZeidan @NEJM I wouldn’t call it practice changing but I would definitely call it a very important landmark trial. As it has prospectively proven what we could have agreed on over a cup of coffee when you break it down. 78 views · 1 likes · 0 reposts · 0 replies Open on X →

Amer Zeidan عامر زيدان ✓@Dr_AmerZeidan7 Sep

@Dr_AmerZeidan Agree Amer! It’s great to bring it into focus particularly after the publication of PARADIGM trial in NEJM. Esentially the same idea, try to offer and bring your AML patients with the best care quality to an aloSCT in poor risk molecular risk according to ELN. Only 55 views · 2 likes · 0 reposts · 0 replies Open on X →

Amer Zeidan عامر زيدان ✓@Dr_AmerZeidan7 Sep

@Dr_AmerZeidan Agree @Dr_AmerZeidan and this is without Ven. Looking at Paradigm trial, this trial and a study we published on Dec-10/Ven vs SOC HMA/Ven it would be interesting to evalute the 3 regimens head to head in young/fit patients, excluding Fav risk group. https://t.co/S3 70 views · 2 likes · 0 reposts · 0 replies Open on X →

Amer Zeidan عامر زيدان ✓@Dr_AmerZeidan6 Sep

As we see more registrational trials rely on EFS as primary endpoint for acute myeloid leukemia trials, this analysis makes excellent points on the FDA-recommended approach to use day 1 of randomization as the date of event for induction phase failure events. This is particularly 1.6K views · 13 likes · 1 reposts · 0 replies Open on X →

Amer Zeidan عامر زيدان ✓@Dr_AmerZeidan6 Sep

@Dr_AmerZeidan @NEJM We have been using Aza/Ven for AML for fit adults . Since 2020! 493 views · 5 likes · 0 reposts · 1 replies Open on X →

Amer Zeidan عامر زيدان ✓@Dr_AmerZeidan6 Sep

I think this is a very important trial that has not received the attention it really deserved. It was the first randomized study (and the largest to date) showing that HMA and IC lead to similar PFS and OS in fit older #AMLsm when most pts have adverse risk and proceed to https:/

3.7K views · 71 likes · 19 reposts · 2 replies Open on X →

Amer Zeidan عامر زيدان ✓@Dr_AmerZeidan6 Sep

@Dr_AmerZeidan @NEJM We have bee giving it over to our patients for around 4 years . 218 views · 1 likes · 0 reposts · 0 replies Open on X →

Amer Zeidan عامر زيدان ✓@Dr_AmerZeidan5 Sep

Do you consider the #Paradigm study, just published in @NEJM, to be practice-changing for #AMLsm? 3.7K views · 6 likes · 4 reposts · 3 replies Open on X →

Amer Zeidan عامر زيدان ✓@Dr_AmerZeidan5 Sep

Looking forward to this excellent meeting on @MDSsm @ESHaematology #ESHMDS2026 in Ireland and hope to meet many of you there... https://t.co/Q3WtaPO9IJ

1.1K views · 16 likes · 0 reposts · 0 replies Open on X →

Frente a cuentas del mismo tamaño

10 publicaciones de los últimos 90 días, junto al rango de 10K–100K seguidores. justo en la mediana de su rango de seguidores.

Visualizaciones medianas802esta cuenta924mediana de 10K–100K

Alcance, %3.01%esta cuenta3.62%mediana de 10K–100K

Interacción, %1.31%esta cuenta1.52%mediana de 10K–100K

Métrica	Esta cuenta	Mediana de 10K–100K	Proporción
Visualizaciones medianas por publicación	802	924	0.87×
Alcance (visualizaciones ÷ seguidores)	3.01%	3.62%	0.83×
Tasa de interacción	1.31%	1.52%	0.86×

Otras cuentas de este rango → Comparar con otra cuenta → Cómo se construyen estas referencias →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

1.1K5 Sep

3.7K

2186 Sep

3.7K

493

1.6K

707 Sep

1.7K

Last 10 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

1.44%5 Sep

0.35%

0.46%6 Sep

2.51%

1.22%

0.89%

2.86%7 Sep

3.64%

1.28%

1.34%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes63.2%134 in total

Reposts12.7%27 in total

Replies4.2%9 in total

Bookmarks19.8%42 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Últimas publicaciones

Frente a cuentas del mismo tamaño

Growth & engagement

Views per post

Engagement rate per post

What the audience does

Cuentas similares